Selecta Biosciences Obtains License for LMB-100 for Mesothelioma, Other Cancers

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, announced that it has licensed a next-generation immunotoxin called LMB-100 from the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH). Per Selecta, the immunotoxin “contains a potent bacterial toxin that binds to mesothelin, a protein expressed in all mesotheliomas, pancreatic adenocarcinomas, and a high percentage of other malignancies, including lung, breast, and ovarian cancers.”

Based on preclinical work, President, CEO and Chairman of Selecta, Werner Cautreels, believes that a combination treatment of the company’s proprietary SVP-Rapamycin and LMB-100 “may allow patients with rare, serious and aggressive forms of cancer to tolerate and benefit from multiple immunotoxin treatment cycles.” Two clinical trials of LMB-100 in patients with mesothelioma and pancreatic cancer are currently underway at the CCR. The trials are intended, in part, to help define the maximum tolerated dose.

Clinical trials are actively recruiting for therapies such as SVP-Rapamycin and LMB-100. These groundbreaking treatments could be effective in helping treat your specific type of mesothelioma.